ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Landscape of clinical trials in cancer cachexia: assessment of trends from 1995-2024.BMC cancer · 2025Pooled it
- Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review.BMJ open · 2024Pooled it
- Pooled it
- Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.Haematologica · 2024Trial
- Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer.JAMA network open · 2026Article
- IBD Care Across Diverse Patient Populations: Changing the Narrative.Digestive diseases and sciences · 2026Review
- Health Inequities in Pancreatic Disorders in the Black/African American Community.Journal of racial and ethnic health disparities · 2026Review
- Eligibility criteria and study phase limit racial/ethnic enrollment in oncology clinical trials.BMC cancer · 2026Article
- Equiflow: An open-source software package for evaluating changes in cohort composition.PLOS digital health · 2026Article
- How Many Anxious Kids in Community Mental Health Would Be Eligible for an RCT? And Does It Matter? Insights from a Naturalistic Sample and a Non-Systematic Review.Children (Basel, Switzerland) · 2026Article
- Article
- Underrepresentation of Racial and Ethnic Minorities in Metastatic Colorectal Carcinoma Clinical Trials Within the United States.Annals of surgery · 2026Article
- Article
- Data-driven trial design: use of target trial emulation to evaluate eligibility criteria in asthma and COPD.Frontiers in medicine · 2026Article
- Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.Communications medicine · 2025Article
- Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2.Journal of comparative effectiveness research · 2025Article
- Enhancing accessibility and impact of digitally enabled clinical trials: the WeShare engagement and equity toolkit.ESMO real world data and digital oncology · 2025Review
- Article
- Review
- Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments.Journal of translational medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
purposeClinical trials determine safety and efficacy of cancer therapeutics and establish standards of care. Minority patient participation in cancer clinical trials is dismal. We aimed to determine the impact of eligibility criteria on disparities in pancreatic ductal adenocarcinoma (PDAC) clinical trial candidacy.
methodsTraditional PDAC trial eligibility criteria were obtained from ClinicalTrials.gov. Patients with PDAC who sought care at Virginia Commonwealth University Health from 2010 to 2019 were included. Clinical data were obtained from billing codes and discrete values in the electronic medical record. Eligibility criteria differences between racial groups were determined using chi-squared tests and unconditional maximum likelihood-based odds ratios.
resultsAmong 676 patients, most identified as Black or White race (42.5% and 51.6%, respectively). Using traditional criteria, Black patients were more likely to be ineligible for participation compared with White patients (42.4%
conclusionTraditional eligibility criteria differentially exclude Black patients from participating in PDAC clinical trials. These criteria perpetuate disparities, limit generalizability, and are often not medically justifiable. Revised criteria may improve participant diversity, without compromising safety or study results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.